1. Scrip
  2. >>Business
  3. >>Deals

Roivant Shopping For Multiple, Transformative Deals

 
• By Jessica Merrill

The company is looking to spend some of the cash it earned on the sale of Telavant on new assets that will join the late-stage pipeline.

pearls
Roivant is seeking new pearls to add to its pipeline • Source: Shutterstock

Roivant Sciences Ltd. is actively pursuing business development deals to build out its late-stage pipeline, with a goal of spending some of the cash it earned on the $7.1bn sale of Telavant to Roche Holding AG last year. CEO Matt Gline told investors during the company’s third quarter sales and earnings call on 13 February that Roivant hopes to bring in “multiple” programs over the next year that would be “transformative” to the late-stage pipeline.

Key Takeaways
  • Roivant is looking to bring in new assets to build out its late-stage pipeline, planning to use some of the windfall from the sale of Telavant to Roche last year.

“The general sort of scope of things we’re looking at, I’d say, match the kinds of deals that we’ve done...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Deals

Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside

 
• By Manas Mishra

Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Asia Deal Watch: Aditum Founds Kalexo With Mabwell To Develop Dual-Target SiRNA Asset

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, Vibha Ravi, and Lisa Takagi

Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.

CSL Locks In Option To Buy VarmX In Blood Clotting Drug Bet

 
• By Manas Mishra

Deal Snapshot: CSL secures exclusive option to acquire VarmX, depending on results for a Phase III trial for its lead compound, VMX-C001, a reversal agent for Factor Xa inhibitors.

More from Business

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

 
• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

GSK Unveils Multi-Billion US Investment As Trump Visits UK

 
• By Andrew McConaghie

The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.